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The link between iron and Alzheimer’s disease (AD) has been mainly investigated with a focus on the local accumulation
of this metal in speciﬁc areas of the brain that are critical for AD. In the present study, we have instead looked at systemic
variations of markers of iron metabolism. We measured serum levels of iron, ceruloplasmin, and transferrin and calculated
the transferrin saturation and the ceruloplasmin to transferrin ratio (Cp/Tf). Cp/Tf and transferrin saturation increased in AD
patients.Cp/Tf ratiosalsocorrelated positively withperoxide levelsandnegatively with serumiron concentrations.Elevated values
of ceruloplasmin, peroxides, and Cp/Tf inversely correlated with MMSE scores. Isolated medial temporal lobe atrophy positively
correlated with Cp/Tf and negatively with serum iron. All these ﬁndings indicate that the local iron accumulation found in brain
areas critical for AD should be viewed in the frame of iron systemic alterations.
1.Introduction
Alzheimer’s disease (AD) is a heterogeneous and progressive
neurodegenerative disorder representing the most common
cause of dementia in the elderly. The disease results from a
complex interaction between predisposing genes, biochem-
ical variables, and environmental factors [1]. The variant
E4 of the APOE gene (APOE4), for example, is widely
recognized to contribute to the risk of developing the more
commonlate-onsetAD[2],whilemutationsinthegenesthat
encode presenilin 1 and 2 and the amyloid precursor protein
(APP)are knowntobecausativefactors ofasmall percentage
of familial and early-onset AD cases.
There is also total agreement on the existence of a link
between AD and oxidative stress phenomena triggered by
transition metals. However, these phenomena have been
generally viewed as originating locally within speciﬁc brain
areas, and autonomously, that is, independently of systemic
inﬂuences. In this frame, authors have reported enhanced
iron concentrations in AD brains, both in autopsy brain tis-
sues and in cerebrospinal ﬂuid (CSF) [3, 4], especially in the
basal ganglia (in vivo: [5, 6]a u t o p s y :[ 7]), in the hippocam-
pus (in vivo: [6, 8]; autopsy: [9, 10]), neocortex (autopsy:
[7, 9, 11]), and around the senile plaques of amyloid beta
(Aβ) or the neuroﬁbrillary tangles commonly found in AD
brains [12–15]. Authorshave also reported altered local con-
centrations of speciﬁc proteins regulating iron levels, such as
ceruloplasmin [16–18], transferrin [7, 19], and ferritin [19].
Recently, a wider and somewhat complementary view
has emerged suggesting a relationship of AD with systemic,
rather than autonomous, changes of metal metabolisms.
Some pilot studies based on this view have focused primarily
on the genes of hemochromatosis (HFE) and of transferrin,
since they play a key role in iron homeostasis, but investi-
gations on circulating markers of iron metabolism are still
relatively scanty.2 International Journal of Alzheimer’s Disease
In the present study, we focused on this aspect and stud-
ied systemic variations of markers of iron metabolism,
such as serum iron, ceruloplasmin, transferrin, transferrin
saturation,andratioofceruloplasmintotransferrin (Cp/Tf),
in a sample of AD patients and in one of healthy elderly
subjects.
2.Subjectsand Methods
Forty-nine AD patients (mean age 75.6) and 46 cognitively
normal individuals (mean age 71.2) were included in the
study (see Table 1). The two samples were slightly diﬀerent
in sex and age; consequently, when appropriate, all statistical
analyses were adjusted for these two confounders. The AD
patient sample consisted of individuals with a clinical diag-
nosis of probable AD based on NINCDS-ADRDA criteria
[20] and with a Mini-Mental State Examination (MMSE)
[21] score of 25 or less. All AD patients underwent neu-
rologic, neuroimaging (magnetic resonance imaging: MRI
or computed tomography: CT), and neuropsychological
evaluation, as well as routine laboratory tests. Average dis-
ease duration (from symptom onset) was 27 (range 6–96)
months.
The control sample consisted of elderly volunteers with
no clinical evidence of neurologic or psychiatric disease.
Twelve AD patients had either poor quality MRI or
reasons not to take it (e.g., metal prostheses). In these cases,
a CT scan was taken to rule out other causes of dementia.
Six AD patients did not complete the entire battery of
neuropsychological tests. The same AD cohort had been
investigated in a previous study [22].
All controls underwent a neurologic examination and
MMSE, but only 12 consented to MRI.
Criteria for exclusion of both patients and controls
were conditions known to aﬀect metal metabolism and
biological variables of oxidative stress, for example, dia-
betes mellitus, inﬂammatory diseases, Hodgkin’s disease,
recent history of heart or respiratory failure, chronic liver
or renal failure, malignant tumors, and alcohol abuse,
assessedbytestsincludingcompletebloodcount,erythrocyte
sedimentation rate (ESR), cholesterol, triglycerides, ferritin
and ﬁbrinogen levels, serum protein electrophoresis, renal
function (creatinine, blood urea nitrogen), fasting glucose,
electrolytes, vitamin B12, and folic acid and uric acid
levels;thyroidfunction tests(thyroxin,triiodothyronine, and
thyrotropin levels); liver enzymes (transaminases), cardiac
enzymes (creatine phosphokinase, lactate dehydrogenase),
bilirubin levels; serology for syphilis, and urine analysis.
Patients and controls with abnormal values of thyroid,
liver, kidney, and cardiac functions were also excluded from
the study.
The study was approved by the local IRB, and all partici-
pants or legal guardians gave written, informed consent.
2.1. Biochemical and Molecular Investigations. Sera from
fasting blood samples were collected in the morning and
rapidly stored at –80◦C. Methods for measuring biological
variables of metals and oxidative stress are described in
Table 1: Characteristics of the study groups.









Mean (SD) 75.6 (7.7) 71.2 (10.8) t test; P = .023
ApoE ε4 allele
frequency (%) 19.6 4 Pearson’s = 6.4
P = .012
MMSE





detail elsewhere [23]. Brieﬂy, hydroperoxide content was
assessed by d-ROMs test (Diacron, Italy) and expressed
in arbitrary units (U.CARR), 1U.CARR corresponding to
0.08mg/100mL of hydrogen peroxide. Normal range was
between 230 and 310U.CARR [23]. Transferrin and ceru-
loplasmin were measured by immunoturbidimetric assays
(Roche, Diagnostic, Germany) utilizing a goat antihuman
transferrin antibody in TRIS/HCl buﬀer and a rabbit anti-
human ceruloplasmin antibody in phosphate buﬀerand iron
using Ferene [20, 21].
All biochemical measures were automated on a Hitachi
912 analyser (Roche Diagnostics) and performed in dupli-
cate. APOE genotyping was performed according to estab-
lished methods [24].
2.2. MRI Evaluation. Brain MRI was performed using a
1.5 Tesla superconductor magnet. The imaging protocol
consisted of axial T2 W double Spin Echo (SE) sequences
and T1 W SE images in axial, coronal, and sagittal planes,
with5mmslicethicknessandintersectiongap =0.5mm.MR
images were evaluatedbytwo experienced neuroradiologists,
blind to the patients’ diagnoses and laboratory results, with
an agreement of about 95%. Atrophy and white matter
lesions were graded following standardized visual rating
scales on plain MRI [25–27]. The degree of medial temporal
lobe atrophy (MTA) was evaluated with a ranking procedure
andvalidatedbylinearmeasurementsofthemedialtemporal
lobe including the hippocampal formation and surrounding
spacesoccupiedbyCSF,following standardized criteria (ﬁve-
point rating scale of MTA) [26]. Generalized brain atrophy
(ventricular and sulcal atrophy) was rated as present (=1)
or absent (=0; global atrophy). The visual rating scale of
white matter changes included the anatomical distribution
as well as the severity of the lesions. Based on anatomical
distribution, a distinction was made between areas of
periventricular hyperintensities (PVH) (caps and rims) and
deeper hyperintensities (including frontal, parieto-occipital,
and temporal white matter hyperintensities: DWMH, basalInternational Journal of Alzheimer’s Disease 3
ganglia hyperintensities: BGH, and infratentorial hyperin-
tensities: ITH). Large vessel cortical infarcts in the anterior,
posterior, and medial cerebral artery were also evaluated.
Presence of mass lesions and lobar hemorrhages was an
exclusion criteria from the study [27, 28].
2.3. Ultrasonographic Examination of the Cerebral Vessels.
The carotid and vertebral arteries were studied by means
of color-coded duplex ultrasonography (7.5MHz probe;
Acuson,Aspen,USA)accordingtostandardized criteria[29].
Detailed description of the sonographic procedures has been
previously reported [30]. Particular attention was paid to
detecting both presence and degree of stenosis of atheroscle-
rotic plaquesin the carotid and vertebralarteries. The intima
and media thickness (IMT) from the distal portion of the
CCA was investigated in detail in each patient according
to previous studies [31]. Intracranial vessels were also
examined by transcranial Doppler (TCD Multidop T TCD-
DWL,Germany), accordingtopreviouslydescribedmethods
[32].
2.4. Statistical Analyses. AD and controls were described in
terms of main demographic, genetic, and cognitive char-
acteristics and statistically compared with either T-o rχ2-
square tests. Both age and sex eﬀects were considered in the
statistical analyses. Correlation analyses between biological
variables, MMSE scores, MRI atrophy, and vascular mea-
surements (Spearman’s rho) were performed. A P value less
than .05 was considered signiﬁcant in all statistical analyses.
The t test was used when the homogeneity of variances
could be assumed. When the variances were statistically
heterogeneous, the Games-Howell procedure was applied.
We used the SPSS 11.5 for Windows statistical software
package (SPSS Inc., Chicago).
3.Results
The two groups diﬀered for MMSE scores (P<. 001). No
diﬀerences for fasting glucose, vitamin B12, folic acid and
uric acid levels, ESR, bilirubin levels, cholesterol, triglyc-
erides, albumin, complete blood count, and hypertension
were detected between the two groups (data not shown).
APOE ε4 allele was more frequent in AD patients (Table 1).
None among the biological variables under study cor-
related with age, with the exception of ceruloplasmin (r =
0.355, P = .01) and peroxides (r = 0.215, P = .039), which
both increased with age (these two variables were corrected
for the age eﬀect before entering the statistical analyses). No
variations on sex eﬀect were found in our data.
Table 2 reports the values of serum iron, ceruloplasmin,
transferrin, transferrin saturation, and Cp/Tf in AD patients
and controls. Transferrin saturation (P = .033) and Cp/Tf
(P<. 001) resulted increased in AD patients compared to
controls (Table 2).
Cp/Tf correlated positively with peroxide levels (r =
0.560, P<. 001) and negatively with serum iron concen-
trations (r =− 0.417, P<. 001). Elevated values of ceru-
loplasmin, peroxides, and Cp/Tf inversely correlated with
Table 2: Serum levels of the investigated variables in AD patients




(n = 46) t test
Iron (ng/dL) 69.3 (27.79) 76.7 (23.6) P = .209
Ceruloplasmin
(mg/dL) 29.9 (5.8) 26.5 (4.6) P = .017
Peroxides
(U.CARR) 349 (63) 310 (56) P = .005
Transferrin
(g/L) 2.5 (0.52) 2.7 (0.35) P = .232
Transferrin
saturation (%) 33.9 (9.6) 30.5 (4.1) P = .03
Cp/Tf 12.4 (3.1) 10 (2.1) P = .001
After correction for age eﬀect.
MMSE scores (Table 3). Correlation analysis from the
Doppler examination revealed that no AD patient had
abnormal ﬂow velocity in the cerebral arteries examined by
Duplexsonography and TCD(resultsnotshown). Moreover,
none of the biochemical variables assayed correlated with
ultrasound indicators of cerebrovascular burden, namely,
presence of carotid plaque or stenosis, except for the IMT
values that correlated with APOE ε4 genotype (Spearman
rho = 0.36; P<. 01) conﬁrming what was previously
reported [20]. Analyses of MRI data showed that presence
of supratentorial atrophy, (enlarged sulci, widened lateral,
and third ventricles), and atrophy of the temporal lobes
(reduction in hippocampal volume), was prominent in AD
subjects, while control subjects’ values were consistent with
those found in normal aging. Among MRI measurements
and serum oxidative-iron markers values, there was a neg-
ative correlation between isolated medial temporal atrophy
(MTA) and serum iron and a positive one between Cp/Tf
and MTA (Table 3). White matter changes and deep-seated
ischemic changes did not correlate with any metal marker as
well as peroxides.
4.Discussion
The results of our comparison between AD patients and
healthy controls show that major markers of circulating
iron status, such as ceruloplasmin, Cp/Tf, transferrin satu-
ration, and peroxides levels, are abnormal in AD patients.
This ﬁnding demonstrates that systemic alterations of iron
metabolism accompany the disease and indicate that the role
attributed by existing literature to local iron accumulations
in brain areas critical for AD should be rather viewed in
the frame of a wider systemic alteration. In this scenario,
antioxidant systems play of course a role. In the present AD
study, as we did previously with stroke patients [33], we used
the Cp/Tf ratio to represent the functionality of one of these
systems, the Cp-Tf system [31], which is otherwise diﬃcult
to monitor biochemically [31].4 International Journal of Alzheimer’s Disease
Table 3: Correlations between outcomes of MMSE, MTA evalua-
tion, and biological variables under study.
Spearman’s rho correlations MMSE MTA
Iron
rho = 0.121 rho =− 0.393
P = .364 P = .008
n = 58 n = 45
Ceruloplasmin
rho =− 0.265 rho = 0.184
P = .040 P = .225
n = 60 n = 45
Peroxides
rho =− 0.329 rho = 0.184
P = .008 P = .211
n = 64 n = 48
Transferrin
rho = 0.113 rho =− 0.269
P = .372 P = .065
n = 65 n = 48
Transferrin saturation
rho =− 0.120 rho = 0.280
P = .336 P = .051
n = 66 n = 49
Ceruloplasmin/transferrinratio
rho =− 0.373 rho = 0.300
P = .004 P = .048
n = 59 n = 44
After correction for sex and age.
In the Cp-Tf system, ceruloplasmin catalyzes the oxida-
tion of ferrous iron (Fe2+) into ferric iron (Fe3+), by way of
the following chemical reaction:
4Fe 2+ +4H + +O 2 −→ 4Fe 3+ +2H 2O. (1)
This is generally viewed as a “good” reaction both because
its byproduct is innocuous water and because, once trans-
formed into Fe3+, iron binds to transferrin by which it is
transported to cells. Ceruloplasmin-catalyzed iron oxidation
and removal from circulation by transferrin is a very impor-
tant process since it reduces the amount of Fe2+ available
for participation in Fenton’s reactions, whose byproducts
are instead extremely vicious. In fact, ferrous iron can also




Fe2+ +H 2O2 −→ Fe3+ +O H
• +O H
− (2)
which, in turn, proceeds as follows:
Fe3+ +H 2O2 −→ Fe2+ +OO H
• +H +. (3)
In other words, if it were not oxidized and removed
by the coordinated ceruloplasmin and transferrin actions,
iron would cyclically produce highly reactive radicals, which
the circulating blood would then distribute all over the
organism. Nonetheless, it is important to keep in mind
that if, on one hand, this mechanism avoids or reduces
production of lethal oxidative species in general circulation
and allows the vital transport of iron to cells, on the other
hand, when iron moves into the cells, as it could be the case
f o rn e u r o n s ,i tc a ns t i l lc a u s ebrain damage if a concomitant
neuronal iron defective eﬄux does occur [34]. Evidence of
a defective iron eﬄux from neurons, linked to APP, was
reported inseveralstudiesoncellculturesandAPPknockout
mice (APP−/−), in which APP expression is experimentally
suppressed [34, 35]. The ablation of APP, which is normally
expressed both in the brain and in a limited number of non-
neural tissues as platelets, liver, kidney, and heart [34, 35],
produces metal disbalance in these organs and tissues. In
particular, some authors [35]d e m o n s t r a t e da ni n c r e a s eo f
copper concentrations in the liver (80%) and in the brain
(40%) in APP−/− mice. Other authors [34]d e m o n s t r a t e d
t h a tA P Pa b l a t i o nc a u s e sa ni r o ni n c r e a s eo f2 6 %i nt h e
brain, 31% in the liver, and 15% in the kidney. They also
showed that, like ceruloplasmin, APP catalytically oxidizes
Fe2+ [34]. All together, these studies demonstrate that APP
plays a role in copper and iron mobilization, indicating that
its abnormalities in AD have either a systemic eﬀect on
those metals’ homeostasis or a local eﬀect on neuronal metal
eﬄux. Our current results of increased brain atrophy (MTA
scores) in ADpatientsare in support to thisconcept,as MTA
scores associate to either decreasing levels of serum iron or
increased values of Cp/Tf ratios. Both these results appear
coherent with the picture of an abnormal activation of the
Cp-Tf system in AD, the subtraction of iron from general
circulation, and its probable internalization into neural cells.
This eventually could cause neuronal death via generation of
oxidative stress in Aβ transition metal(s) reactions [2].
Finally, in the same direction go also our results on
MMSE scores, which worsen with increasing Cp/Tf ratios.
Ceruloplasmin increase and transferrin decrease concen-
trations were identiﬁed in diverse pathological conditions
as an important defense mechanism reﬂecting the body’s
resistance to an oxidant insult [36]. This is the case, for
example, in severe preeclampsia, where women have high
levelsoflipidperoxidationandserumceruloplasminandlow
levelsof transferrin [37, 38],in acutestroke,where the Cp/Tf
correlates with the severity of the clinical status [33], or in
experimental hypercholesterolemia [36].
Ceruloplasmin increase and transferrin decrease concen-
trations are also reported as a sign of inﬂammation in a
number of conditions spanning from cardiac to psychiatric.
In fact, these proteins are acute phase reactants (positive and
negative, resp.), produced by the liver together with several
other proteins.
Another protein aﬀecting iron homeostasis is HFE,
a membrane protein which controls iron absorption by
regulating the aﬃnity of transferrin receptors on cell
membrane [39]. Speciﬁc mutations of the HFE gene cause
hemochromatosis, that is, an increased absorption of dietary
iron and itsconsequentoverdeposition in tissues and organs
[40]. Recently, a number of studies have shown various
relationships between AD and mutations of the HFE, as well
as the transferrin, genes but reported data are controversial
andfarfromunivocalinterpretation[41–46].Inaveryrecent
study of ours, we found that the synergy of altered markers
of iron status (iron levels, transferrin, transferrin saturation,
ferritin, and Cp/Tf ratio) and mutations of the HFE gene can
increase the probability of developing AD (submitted).
Overall, Cp-Tf antioxidant system represents the serum
capacityto sequesterexchangeable metals(copper,iron) [36]International Journal of Alzheimer’s Disease 5
which make a labile metal pool prone to partake in reactions
generating oxidative damage [47, 48]. Previous studies of
altered levels of this labile metal pool in AD, especially
referred to a serum increase of “free” copper, that is, the
quantity of copper which is not bound to ceruloplasmin,
sustain this concept [49, 50]. Support to this notion comes
also from a study of our laboratory showing lower cortical
responses in depressed patients who presented lower trans-
ferrin and higher free copper serum levels [51].
As a whole the data presented are in agreement with the
past key works by both Loeﬀer’s [16] and Castellani’s [17]
groups, who reported higher ceruloplasmin levels in brain
areas critical for AD. However, the relationship between
systemic processes and local eﬀects in the brain is the main
focus of our laboratory’s work in progress.
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